Eledon Pharmaceuticals, Inc. (ELDN)
Market Cap | 33.24M |
Revenue (ttm) | n/a |
Net Income (ttm) | -38.39M |
Shares Out | 13.76M |
EPS (ttm) | -2.67 |
PE Ratio | n/a |
Forward PE | 2.19 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 15,713 |
Open | 2.45 |
Previous Close | 2.37 |
Day's Range | 2.36 - 2.68 |
52-Week Range | 1.90 - 4.14 |
Beta | 2.04 |
Analysts | Buy |
Price Target | 18.56 (+668.21%) |
Earnings Date | May 10, 2023 |
About ELDN
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the trea... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ELDN stock is "Buy." The 12-month stock price forecast is $18.56, which is an increase of 668.21% from the latest price.
News

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET

Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the upco...

Eledon Pharmaceuticals Provides Business and Pipeline Updates
Company plans to prioritize and focus resources on the advancement of tegoprubart in kidney transplantation

C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
Eledon to Incorporate the iBox Scoring System in Future Kidney Transplant Trials Eledon to Incorporate the iBox Scoring System in Future Kidney Transplant Trials

Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
Received FDA clearance of IND application to evaluate tegoprubart in a Phase 2 trial for the prevention of rejection in patients receiving a kidney transplant

Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

Eledon Pharmaceuticals Announces Upcoming Presentations at ASN's Kidney Week 2022 and NEALS
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the Company will present two posters at the upcoming American Society of ...

Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in a ...

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's In...

Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences
IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming investor conferences:

Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results
Received FDA clearance of IND application for Phase 2 trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients

Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
Management to host conference call and webcast at 4:30 pm ET

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inn...

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IRVINE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inn...

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis
IRVINE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inno...

Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results
Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022

Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET

Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference
IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of in...

Eledon to Host Virtual R&D Day on Thursday, April 28, 2022
IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of in...

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference
IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inn...

Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences
IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inn...

Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results
Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022

Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D.
Presentation to focus on potential use of AT-1501 in kidney transplantation as well as research collaboration between Eledon and CareDx to help assess the efficacy of Eledon's investigational AT-1501 ...